U.S. Global Investors (USGI)’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

U.S. Global Investors (USGI)’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-18,800	Closed	-$1.13M	–	212
2019 Q4	$1.13M	Buy	+18,800	New	+$1.12M	0.51%	61
2018 Q2	–	Sell	-19,200	Closed	-$1.01M	–	166
2018 Q1	$1.01M	Buy	+19,200	New	+$1.12M	0.62%	49
2017 Q4	–	Sell	-12,600	Closed	-$751K	–	176
2017 Q3	$751K	Sell	12,600 -1,300	-9%	-$78.6K	0.22%	85
2017 Q2	$1.1M	Buy	+13,900	New	+$1.14M	0.38%	61

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

U.S. Global Investors (USGI)'s EGRX Position: Q1 2020 in Review

U.S. Global Investors (USGI) sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2020, closing a stake of 18,800 shares — an estimated $1.13M sold.

U.S. Global Investors (USGI) first reported a position in EGRX in Q2 2017 and held it in 4 quarters. The position peaked at $1.13M in Q4 2019. 168 funds tracked by Wall St. Rank hold EGRX as of Q1 2020.

U.S. Global Investors (USGI) reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
U.S. Global Investors (USGI) sold 18,800 Eagle Pharmaceuticals, Inc. shares in Q1 2020, an estimated $1.13M.
U.S. Global Investors (USGI) first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2017 and held it in 4 quarters.
U.S. Global Investors (USGI)'s Eagle Pharmaceuticals, Inc. position peaked at $1.13M in Q4 2019.
168 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2020.

Based on U.S. Global Investors (USGI)'s 13F filing for Q1 2020, filed 4 May 2020.